Jane Street’s Sagimet Biosciences SGMT Stock Holding History

Jane Street’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$411K	Buy	+53,200	New	+$362K	﹤0.01%	8487
2025 Q3	–	Sell	-28,400	Closed	-$216K	–	11666
2025 Q2	$216K	Buy	+28,400	New	+$120K	﹤0.01%	8415

Other funds holding SGMT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jane Street's SGMT Position: Q2 2026 in Review

Jane Street sold out of Sagimet Biosciences (SGMT) in Q2 2026, closing a stake of 17,187 shares — an estimated $117K sold.

Jane Street first reported a position in SGMT in Q1 2024 and held it in 8 quarters. The position peaked at $547K in Q4 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

Jane Street reported no remaining Sagimet Biosciences position as of Q2 2026 after selling out during the quarter.
Jane Street sold 17,187 Sagimet Biosciences shares in Q2 2026, an estimated $117K.
Jane Street first reported a position in Sagimet Biosciences in Q1 2024 and held it in 8 quarters.
Jane Street's Sagimet Biosciences position peaked at $547K in Q4 2025.
122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.